DEF: Local Bounti Seeks Shareholder Approval for $10M U.S. Bounti Deal

Local Bounti Corporation is calling a special meeting to approve the issuance of common stock to its majority shareholder, U.S. Bounti, related to a $10 million convertible note and warrant agreement.

Summary

• Local Bounti Corporation is holding a Special Meeting of Stockholders on October 14, 2025, to vote on two proposals.
• The primary proposal (NYSE Approval Proposal) seeks approval for the issuance of up to 5,131,871 shares of common stock upon conversion of a $10.0 million convertible note and up to 550,000 shares underlying a common stock purchase warrant, both issued to U.S. Bounti, LLC.
• This approval is required by NYSE rules because U.S. Bounti is an "Active Related Party" and the share issuance exceeds 1% of outstanding common stock (22,103,180 shares before the agreement), and the conversion/exercise prices were below the NYSE Minimum Price.
• The convertible note has an initial principal balance of $10.0 million and an initial conversion price of $2.50 per share, accruing interest at 6.0% annually (PIK interest).
• The warrant is exercisable at $0.125 per share and expires 10 years from August 1, 2025.
• The second proposal (Adjournment Proposal) seeks approval to adjourn the Special Meeting if insufficient votes are received for the NYSE Approval Proposal.
• The Board of Directors unanimously recommends voting FOR both proposals.

Sentiment

Score: 5

Explanation: The filing describes a necessary financing transaction that provides capital but also highlights significant dilution and the substantial control of a single shareholder. While the capital is positive, the terms and the existing ownership structure present notable risks and potential conflicts of interest for other shareholders, leading to a neutral-to-slightly-negative sentiment.

Positives

• Secures $10.0 million in financing through a convertible note and warrant agreement with U.S. Bounti, providing capital for working capital and general corporate purposes.
• The financing includes a convertible note with an initial conversion price of $2.50 per share and a warrant exercisable at $0.125 per share, potentially strengthening the company's capital structure.
• The Board of Directors unanimously supports the proposals, indicating management's belief in the transaction's benefit to the company and stockholders.

Negatives

• The issuance of new shares upon conversion of the note and exercise of the warrant will have a dilutive effect on current stockholders (other than U.S. Bounti), reducing their percentage ownership.
• The conversion price of the note ($2.50) and the exercise price of the warrant ($0.125) were below the NYSE Minimum Price, indicating a potentially unfavorable valuation for the issuance.
• Failure to obtain stockholder approval for the NYSE Approval Proposal will obligate the company to call additional special meetings every four months, incurring additional costs.
• The concentration of ownership by Charles R. Schwab (60.4% beneficial ownership) through U.S. Bounti and other entities allows significant influence over company decisions, potentially not aligning with other stockholders' interests.

Risks

• Dilution: The issuance of up to 5,131,871 shares from the convertible note and 550,000 shares from the warrant will dilute the percentage ownership of existing stockholders (excluding U.S. Bounti).
• Trading Price Impact: Potential sales of registered Conversion Shares and Warrant Shares by U.S. Bounti could adversely affect the trading price of common stock.
• Control by Majority Shareholder: Charles R. Schwab, through U.S. Bounti, controls 60.4% of outstanding common stock, enabling significant influence over corporate decisions, including director elections and significant transactions, potentially delaying or blocking a change in control.
• Additional Costs: Failure to approve the NYSE Approval Proposal will result in the company incurring additional costs by being obligated to call subsequent special meetings every four months until approval is obtained.

Future Outlook

The company expects the NYSE Approval Proposal to receive a sufficient number of votes at the Special Meeting. If approved, U.S. Bounti may convert the note and exercise the warrant without additional stockholder approval. If not approved, the company will incur additional costs by calling subsequent special meetings every four months until approval is obtained.

Management Comments

• The Board and our management support the NYSE Approval Proposal and believe it to be in the best interests of Local Bounti and our stockholders.
• We expect that the NYSE Approval Proposal will receive a sufficient number of votes at the Special Meeting to ensure that it is approved.
• The Board believes that, if the number of shares voting in favor of the NYSE Approval Proposal is insufficient to approve such item, it is in the best interests of our stockholders to enable the Board, for a limited period of time, to continue to seek to obtain a sufficient number of additional votes in favor of the proposal.

Industry Context

This filing primarily concerns a specific financing transaction and related corporate governance requirements, rather than broader industry trends. The company operates in the controlled environment agriculture (CEA) or indoor farming sector, and the capital raise is intended for working capital and general corporate purposes, including potential capital expenditures at a greenhouse facility, which aligns with ongoing investment needs in this capital-intensive industry.

Corporate Governance

Related Party Transactions

• Convertible Note and Warrant Purchase Agreement dated August 1, 2025, between Local Bounti Corporation and U.S. Bounti, LLC, the company's majority stockholder.
• U.S. Bounti, LLC is controlled by Charles R. Schwab, who beneficially owns 60.4% of the company's outstanding common stock.
• The transaction involves the issuance of a $10.0 million convertible note and a warrant for 550,000 shares to U.S. Bounti.
• The issuance requires stockholder approval under NYSE rules because U.S. Bounti is an "Active Related Party" and the issuance exceeds 1% of outstanding common stock, with conversion/exercise prices below the NYSE Minimum Price.

Stakeholder Impact

• Shareholders (excluding U.S. Bounti): Will experience dilution of their percentage ownership and potential adverse impact on the trading price of common stock if the Conversion Shares and Warrant Shares are issued and subsequently sold.
• U.S. Bounti (Majority Shareholder): Will receive additional equity in the company, potentially increasing its control and influence, and benefits from the terms of the convertible note and warrant.
• Company: Secures $10.0 million in financing for working capital and general corporate purposes, but faces potential additional costs if stockholder approval is not obtained promptly.
• Employees: No direct impact mentioned, but a stronger financial position could indirectly benefit employees through continued operations.

Next Steps

• Stockholders to vote on the NYSE Approval Proposal and the Adjournment Proposal at the Special Meeting on October 14, 2025.
• If the NYSE Approval Proposal is approved, U.S. Bounti may convert the note and exercise the warrant.
• If the NYSE Approval Proposal is not approved, the company is obligated to call additional special meetings every four months until approval is obtained.
• The company intends to file a registration statement with the SEC to register the Conversion Shares and Warrant Shares for resale by U.S. Bounti following approval.

Key Dates

Recommendation

The filing details a crucial capital injection of $10 million via a convertible note and warrant, which is positive for Local Bounti's liquidity and operations, particularly for working capital and specific capital expenditures. However, the transaction involves significant dilution for existing shareholders (excluding the majority holder, U.S. Bounti) and reinforces the substantial control of Charles R. Schwab, who already beneficially owns over 60% of the company. The conversion and exercise prices being below NYSE minimums suggest potentially unfavorable terms for other shareholders. While the capital is necessary, the dilutive effect and the concentration of control present notable risks. Given these mixed signals – essential financing versus significant dilution and control issues – a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring the company's operational execution and the market's reaction to the increased ownership concentration and potential future share sales.

Keywords

Local Bounti Corporation, SEC filing, DEF 14A, proxy statement, stockholder meeting, convertible note, warrant, U.S. Bounti, Charles R. Schwab, NYSE rules, share issuance, dilution, corporate governance, related party transaction, capital raise, LOCL